Abstract: The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, (iii) a hydrophobic moiety, and (iv) a crosslinking moeity, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an RNA and/or DNA) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.

Abstract: An organic light emitting diode (OLED) includes an emissive layer with at least one emitting part includes at least one emitting material layer, a first electron transport layer and a second electron transport layer disposed sequentially between two facing electrodes, wherein the first electron transport layer includes a first electron transporting material of a benzimidazole-based compound substituted with at least one spiro-structured fluorenyl group and the second electron transport layer includes a second electron transporting material of a benzimidazole-based compound substituted with at least one anthracenyl group. The first electron transport including the first electron transport material with excellent thermal stability is disposed adjacently to the emitting material layer so that the OLED can maintain good luminescent intensity in an environment of high temperature and implement beneficial luminous properties.

Abstract: Disclosed are a light-emitting device and a display device including the same. An emissive layer is formed so as to have a dual-layer structure, the triplet energy level of a dopant of a first emissive layer adjacent to a hole transport layer is greater than the triplet energy level of a first host in the first emissive layer, and the triplet energy level of the first host is greater than the triplet energy level of a second host of a second emissive layer, whereby triplet excitons generated in the first emissive layer are recycled to the second emissive layer so as to be reused for light emission.

Abstract: A vehicle body structure for safely protecting a high-voltage, the vehicle body structure including: a battery mounted on bottom portions of a center floor and a rear floor; and a protective structure having a bottom portion on which a peripheral portion of the battery is mounted and including panels fitted to each other into a shape covering a peripheral portion of the center floor.

Abstract: Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered immune cells. Certain embodiments of the disclosure include compositions, cells, and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and may be suitable for allogeneic cellular therapy because they are HLA negative. In some aspects, the cells have imaging and suicide targeting capabilities.

Abstract: A vehicle body structure for safely protecting a high-voltage, the vehicle body structure including: a battery mounted on bottom portions of a center floor and a rear floor; and a protective structure having a bottom portion on which a peripheral portion of the battery is mounted and including panels fitted to each other into a shape covering a peripheral portion of the center floor.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor.

Abstract: Compositions are provided including NK cells that express chimeric antigen receptors (CARs) specific to CD19 and Her2 and a plurality of cell surface-bound multilamellar liposomal vesicles loaded with one or more anti-cancer therapeutics at an effective amount for inhibiting or killing tumor cells without causing toxicity to the NK cells. Methods of using these compositions to treat a subject with tumor are also provided, including administering an effective amount of the CAR-engineered NK cells, where an effective amount of anti-tumor therapeutics are delivered in particles (e.g., crosslinked multilamellar liposomal vesicles) that are bound to the surface of these CAR-engineered NK cells, without causing toxicity to the carrier NK cells.

Abstract: Described herein are compositions including an immune effector cells that are chemically modified at the surface with one or more active agent-loaded nano- or micro-particles for controlled release of the active agent. Exemplary drug-loaded nanoparticles include crosslinked multilayer liposome (CMLV) encapsulating an A2a receptor inhibitor. The modified immune effector cells may also present one or more chimeric antigen receptors (CARs) on the surface. Also provided are methods of using the same to treat cancer.

Abstract: The present invention relates to a gastric-retention type sustained-release formulation of metformin as an insulin-independent diabetic agent, and a preparation method thereof. More specifically, the present invention relates to a gastric-retention type sustained-release formulation, which can effectively control drug release even with a small amount of a polymer by forming a sustained-release granulated material, which comprises granules containing metformin or a pharmaceutically acceptable salt thereof and a swellable polymer, and a water-insoluble coated on the surface of the granules; and also can allow a tablet containing the drug to swell rapidly at an early stage by formulating via mixing of a superdisintegrant, which is capable of controlling the speed of gelation forming hydrogels, with the granulated material; and a preparation method thereof.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor, and has effectively improved stability by blocking physical and chemical reactions between the active ingredients while securing the stable release of respective active ingredients.

Abstract: Provided are an apparatus for integrated real-time nucleic acid analysis and a method for detecting target a nucleic acid using the same, and more particularly an integrated real-time nucleic acid analysis for simultaneously performing qualitative analysis or quantitative analysis on genes from various kinds of plural biological samples and a method for detecting target a nucleic acid using the same. The apparatus for integrated real-time nucleic acid analysis and the method for detecting target a nucleic acid using the same according to the present invention, perform tests of various targets required from various samples through a single step promptly and accurately, and thus, can be efficiently used by hospitals or the like needing to rapidly diagnose diseases.